The global medtech contract development and manufacturing organisation market reached $96.5 billion (€89.2 billion) in 2025, reflecting 8.4% year-over-year growth, and is projected to expand to $143.6 billion (€132.8 billion) by 2030 at a compound annual growth rate of 8.3%, according to the sixth annual CDMO report published by Massachusetts-based global healthcare consulting firm Alira Health, as reported by the Manila Times.

The report identifies pharma-medtech convergence as a defining accelerator of growth, driving increased demand for integrated capabilities across drug and device development and manufacturing.

Drug delivery systems emerged as the largest and fastest-growing segment, valued at $15.2 billion (€14.1 billion) in 2025 and projected to grow at a 9.1% CAGR through 2030, driven by demand for combination products and the continued expansion of GLP-1 therapies.

Deal activity reflected accelerating consolidation, with 54 global transactions completed in 2025. Activity intensified in the second half of the year, with 22% of deals targeting drug delivery as consolidation centred on CDMOs capable of bridging pharma and medtech development cycles.

Gabriele Brambilla, chief executive of Alira Health, said: "The boundaries between pharma and medtech are dissolving, and CDMOs are evolving from manufacturers into indispensable strategic partners."

CDMOs are expanding beyond traditional manufacturing into analytical testing, formulation support, and fill-finish services, with investments in micro-molding, sterile packaging, and precision machining prominent across 2025 transactions.

CDMOs capable of integrating cross-sector expertise and delivering end-to-end solutions are expected to be best positioned to capture future market growth.

Access the full report for a comprehensive breakdown of 2025 CDMO market trends and projections.